Secreted protein, ZTNF9
OwnerBrian A. Fox, Jane A. Grossinventors
Life of this patent
Estimating the term…
Abstract
Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
Claims30
An isolated polypeptide comprising a sequence of amino acid residues from amino acid residue 62 to amino acid residue 81 as shown in SEQ ID NO:2.
An antibody that specifically binds to an epitope of a polypeptide of SEQ ID NO:2.
A method of producing an antibody comprising the following steps in order:
- inoculating an animal with a polypeptide selected from the group consisting of:
- a) a polypeptide consisting of amino acid residues 68 to 82 as shown in SEQ ID NO:2;
- b) a polypeptide consisting of amino acid residues 20 to 87 as shown in SEQ ID NO:2;
- and
- c) a polypeptide consisting of amino acid residues to 87 as shown in SEQ ID NO:2;
- wherein the polypeptide elicits an immune response in the animal to produce the antibody;
- and isolating the antibody from the animal;
- wherein the antibody specifically binds to the amino acid sequence of SEQ ID NO:2 from amino acid number 1 to amino acid number 87.
An isolated polynucleotide encoding the amino acid sequence from amino acid residue 62 to amino acid residue 81 as shown in SEQ ID NO:2.
A method for detecting a genetic abnormality in a patient, comprising:
- obtaining a genetic sample from a patient;
- incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:
- 1 or the complement of SEQ ID NO:
- 1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product;
- comparing said first reaction product to a control reaction product, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
A method for the treatment of a mammal having a need for a ZTNF9 polypeptide comprising administering to said mammal a pharmaceutically effective amount of the polypeptide selected from the group consisting of:
- a) a polypeptide comprising a sequence of amino acids from amino acid residue 20 to amino acid residue 87 of SEQ ID NO:2;
- and
- b) a polypeptide having a sequence of amino acid residues that are at least 80% identical to (a).
A method for the treatment of a mammal having a need for an antagonist of a ZTNF9 polypeptide comprising administering to said mammal a pharmaceutically effective amount of an antagonist of a polypeptide selected from the group consisting of:
- a) a polypeptide comprising a sequence of amino acids from amino acid residue 20 to amino acid residue 87 of SEQ ID NO:2;
- b) a polypeptide having a sequence of amino acid residues that are at least 80% identical to (a).
Dependencies are inferred from the claim text.